Joyvié Health Raises $1.04M to Redesign Continence Care

Jan de Vries · 2026-06-05

In a market that has seen little innovation for decades, UK-based Joyvié Health just closed a pre-Seed round of $1.04 million (€897k) to rethink continence underwear. The company's goal is simple but profound: design a product that actually reduces stool-to-skin contact, protects skin integrity, and lightens the load on caregivers. ### The Funding Breakdown The round includes an Innovate UK grant plus investments from HERmesa Angels, SyndicateRoom, Lavender Ventures, and several individual angel investors. It's a vote of confidence in a deeply personal mission. "Products designed for care should never cause harm. That's not a vision statement. It's the reason this company exists," says Zoe Robson, Founder & CEO of Joyvié Health.  ### A Personal Story Behind the Mission Joyvié Health was born from tragedy. Zoe's father, Fred, was 77 and in great shape when he got a late-stage pancreatic cancer diagnosis on Christmas Eve 2024. Eleven weeks later, he passed away. During those weeks, Fred lost bowel control and had to wear adult nappies. Here's the problem: when feces stays pressed against skin, moisture, pathogens, and pH imbalances break it down fast. That damage never fully heals. Fred's skin broke down, and his dignity eroded with every change. His wife Ruth, the primary caregiver, carried an invisible burden that was impossibly heavy. "My parents didn't deserve that," Zoe says. "They were both at their most vulnerable, and the product meant to help them was making it worse. The skin breakdown, the shame, the loss of dignity, the weight on my mom. It wasn't from lack of care. It's a design failure." ### How Joyvié's Product Works The current standard for non-invasive continence care is nappies and pads, which trap stool against the skin. Joyvié's underwear contains feces in a disposable pouch right after excretion. Early tests show about a 90% reduction in stool-to-skin contact and approximately 70% faster changes. That's a huge leap forward. ### The Broader HealthTech Landscape in 2026 Joyvié's round is part of a wave of HealthTech funding in the UK and Europe. Here's what else happened in adjacent areas: - **Semble** raised $40.5 million (€34.7M) for its outpatient healthcare platform - **Evaro** secured $24.5 million (€21M) for NHS-licensed health services - **JAAQ** closed $17.5 million (€15M) for enterprise mental health partnerships - **Calibre** emerged with $3.3 million (€2.8M) for health diagnostics - **Nul** raised $980k (€840k) for alcohol-dependence care In Europe: - **Recare** (Berlin) raised $43.2 million (€37M) for AI hospital tools - **Patronus** secured $12.8 million (€11M) for senior smartwatches - **Tucuvi** raised $19.8 million (€17M) for voice-AI nursing automation - **Ditto** (Rotterdam) raised $8.9 million (€7.6M) for medical translation - **ShanX Medtech** secured $28 million (€24M) for antimicrobial diagnostics - **MedVasc** raised $2.6 million (€2.2M) for anesthesia catheters All told, that's over $202 million in related 2026 HealthTech funding. ### A Market Ripe for Change "At Lavender Ventures, we are committed to backing founders addressing large, underserved markets with innovative solutions that can meaningfully improve people's lives," says Gail Armstrong of Lavender Ventures. "We believe the market is ripe for innovation, and Joyvié's approach has the potential to deliver significant benefits not only for individuals, but also for carers, healthcare systems, and the environment." ### The Scale of the Problem Faecal incontinence affects an estimated 656 million people worldwide. Yet the most common non-invasive solution hasn't changed in decades. Joyvié Health is out to end that silent humiliation, one product at a time.